argenx (ARGX.BR) Stock Price

The main competitors of argenx SE in the market include companies such as Genmab A/S, Alexion Pharmaceuticals Inc., and MorphoSys AG.

The business model of argenx SE revolves around developing and commercializing innovative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. With an emphasis on the discovery and development of uniquely differentiated antibody-based therapies, argenx combines its expertise in immunology and antibody engineering to target specific disease indications. The company focuses on both in-house discovery programs as well as collaborations with global partners to advance its pipeline of potential breakthrough treatments. By leveraging its expertise and strategic partnerships, argenx aims to bring transformative therapies to market and improve the lives of patients suffering from severe diseases.

argenx SE is a renowned biotechnology company with a rich history and significant accomplishments. Founded in 2008, argenx focuses on the discovery and development of innovative antibody-based therapeutics to benefit patients with severe autoimmune diseases and cancer. The company utilizes its unique Simple Antibody platform to engineer and manufacture differentiated therapeutic antibodies. Throughout its history, argenx has achieved numerous milestones, including successful clinical trials and collaborations with leading pharmaceutical companies. With its dedicated team of scientists and commitment to scientific excellence, argenx SE continues to make groundbreaking contributions in the field of biotechnology.

argenx SE has achieved several significant milestones in its history. It successfully completed a Phase 3 clinical trial for its product candidate efgartigimod, which demonstrated positive results in the treatment of generalized myasthenia gravis. The company also obtained breakthrough therapy designation from the U.S. FDA for efgartigimod in the same indication. Furthermore, argenx SE entered into strategic collaborations with multiple pharmaceutical companies to develop and commercialize its innovative antibody-based therapies. These partnerships include agreements with Janssen for cusatuzumab, Cilag GmbH International for ARGX-112, and Leo Pharma for ARGX-112. Overall, argenx SE has made significant strides in its quest to develop transformative medicines for patients.

argenx SE is primarily present in various countries and regions around the world. The company has a global presence, with key operations and offices located in Europe, particularly in Belgium and the Netherlands. Additionally, argenx SE has expanded its footprint to North America, with offices and clinical development activities in the United States. Through its international presence, argenx SE aims to capitalize on the opportunities available in different markets and establish a strong presence in the biotechnology and pharmaceutical industry.

argenx SE is a biotechnology company that represents a strong set of values and corporate philosophy. With a focus on patients, collaboration, and innovation, argenx aims to transform the lives of people suffering from severe autoimmune diseases and cancer. The company is committed to developing breakthrough therapies based on its unique antibody engineering platform. By combining cutting-edge science, strategic partnerships, and a patient-centered approach, argenx strives to create meaningful impact in the healthcare industry. With its dedication to excellence and a relentless pursuit of scientific advancements, argenx SE has become a leading player in the biotech sector.

Analysts currently set an average price target of 985.38 USD for the argenx stock (median: 981.70 USD), implying +12.5 % versus the latest price. The consensus is based on 25 analyst ratings.

argenx Analyst Price Targets 2026

25 analysts currently rate the argenx stock: 22 recommend buying, 3 holding and 0 selling. For 2026, analysts expect argenx to generate revenue of 6.46 B USD and earnings per share of 30.38 USD.

argenx Analyst Price Targets 2026

Converted at the current exchange rate, the argenx share trades at 780.10 EUR (875.78 USD).

The argenx share (ARGX.BR) is listed on 8 stock exchanges, including: London (0QW0.L), Frankfurt (1AE.F), München (1AE.MU), Düsseldorf (1AE.DU), Wien (ARGX.VI).

argenx SE is a biopharmaceutical company involved in the development and commercialization of therapeutic antibodies. The company operates in various areas, including antibody discovery, data collection, clinical development, manufacturing, and drug marketing. Their research focuses on autoimmune diseases, inflammatory diseases, and cancer. arGEN-X has successfully completed numerous clinical trials and has a wide range of products in various stages of development. The company also seeks partnerships with other biopharmaceutical companies to accelerate the development of new products. Their goal is to discover, develop, and market novel antibodies to treat seriously ill patients.

The expected revenue of argenx is 6.46 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of argenx is 2.01 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of argenx is currently 28.82. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the argenx stock.

The price-to-sales ratio (P/S) of argenx is currently 8.98. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the argenx stock.

The Eulerpool Quality Score for argenx is 7/10.

The ISIN of argenx is NL0010832176. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of argenx is A11602. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of argenx is ARGX.BR. The ticker symbol is used to trade argenx shares on the stock exchange.